Ahmad HA, Alemao E, Guo Z, Iannaccone CK, Frits ML, Weinblatt M, Shadick NA
Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort. Adv Ther. 2018 02; 35(2):232-242.
Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort.
Fleischmann R, Wollenhaupt J, Cohen S, Wang L, Fan H, Bandi V, Andrews J, Takiya L, Bananis E, Weinblatt ME
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther. 2018 Jun; 5(1):203-214.
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
Weinblatt ME, Baranauskaite A, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Baek I, Ghil J
Arthritis & rheumatology (Hoboken, N.J.)
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Arthritis Rheumatol. 2018 06; 70(6):832-840.
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Weinblatt ME, Reda D, Henderson W, Giobbie-Hurder A, Williams D, Diani A, Docsa S
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol. 1999 Oct; 26(10):2123-30.
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.
The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol. 1992 Nov; 19(11):1678-82.
The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis.
van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, Lipsky P
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002 Apr 15; 47(2):215-8.
How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion.
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan; 48(1):35-45.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Spragg J, Weinblatt ME, Coblyn J, Fraser P, Austen KF
The Journal of laboratory and clinical medicine
Effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis. J Lab Clin Med. 1988 Sep; 112(3):324-32.
Effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.
Hu Y, Carman JA, Holloway D, Kansal S, Fan L, Goldstine C, Lee D, Somerville JE, Latek R, Townsend R, Johnsen A, Connolly S, Bandyopadhyay S, Shadick N, Weinblatt ME, Furie R, Nadler SG
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids. Arthritis Rheumatol. 2018 08; 70(8):1331-1342.
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids.
Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 2006 Apr; 33(4):659-64.
Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study.
Fatal Mycoplasma pneumoniae encephalitis in an adult. Arch Neurol. 1980 May; 37(5):321.
Fatal Mycoplasma pneumoniae encephalitis in an adult.
Rheumatoid factor detection by nephelometry. Arthritis Rheum. 1980 Jun; 23(6):777-9.
Rheumatoid factor detection by nephelometry.
Methotrexate for chronic diseases in adults. N Engl J Med. 1995 Feb 02; 332(5):330-1.
Methotrexate for chronic diseases in adults.
Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 1989 Dec; 32(12):1592-6.
Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy.
Kjelgaard-Petersen CF, Platt A, Braddock M, Jenkins MA, Musa K, Graham E, Gantzel T, Slynn G, Weinblatt ME, Karsdal MA, Thudium CS, Bay-Jensen AC
Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis Rheumatol. 2018 09; 70(9):1419-1428.
Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
Yu Z, Yang N, Everett BM, Frits M, Iannaccone C, Coblyn J, Weinblatt M, Shadick N, Solomon DH, Liao KP
Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis. Arthritis Rheumatol. 2018 09; 70(9):1392-1398.
Impact of Changes in Inflammation on Estimated Ten-Year Cardiovascular Risk in Rheumatoid Arthritis.
Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):846-54.
A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis.
Progress in clinical and biological research
Human renal kallikrein-kinin system after engraftment and/or immunosuppression. Prog Clin Biol Res. 1989; 297:325-38.
Human renal kallikrein-kinin system after engraftment and/or immunosuppression.
Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, Lee DM
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science. 2010 Jan 29; 327(5965):580-3.
Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.
The liver in rheumatic diseases. Semin Arthritis Rheum. 1982 May; 11(4):399-405.
Scimeca PG, Weinblatt ME, Kahn E, Kochen JA
Does rapidly progressive iron overload in a young girl with sideroblastic anemia also signify the presence of hereditary hemochromatosis? Pediatr Hematol Oncol. 1994 Jan-Feb; 11(1):99-104.
Does rapidly progressive iron overload in a young girl with sideroblastic anemia also signify the presence of hereditary hemochromatosis?
RAPID: rheumatoid arthritis. J Fam Pract. 2007 Apr; 56(4 Suppl):S1-7; quiz S8.
Shadick NA, Zibit MJ, Iannaccone CK, Thrower R, Sowell NF, Weinblatt ME, Solomon DH, Cui J
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis. J Clin Rheumatol. 2018 Sep; 24(6):346-349.
A Development and Feasibility Study of a Peer Support Telephone Program in Rheumatoid Arthritis.
Optimal use of methotrexate: the advantages of tight control. Ann Rheum Dis. 2007 Nov; 66(11):1409-10.
Optimal use of methotrexate: the advantages of tight control.
Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, Li J, Louie J, Furst DE
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008 Jul; 58(7):1921-30.
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, Solomon DH
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J. 2008 Aug; 156(2):336-41.
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis.
Questions and answers in 2008 about biologics in rheumatoid arthritis. J Rheumatol. 2008 Sep; 35(9):1878-81.
Questions and answers in 2008 about biologics in rheumatoid arthritis.
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis. 2008 Dec; 67 Suppl 3:iii2-25.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, Baumgartner SW
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol. 2011 Feb; 38(2):242-6.
Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate.
Mease PJ, Genovese MC, Weinblatt ME, Peloso PM, Chen K, Othman AA, Li Y, Mansikka HT, Khatri A, Wishart N, Liu J
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2018 11; 70(11):1778-1789.
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
Methotrexate: who would have predicted its importance in rheumatoid arthritis? Arthritis Res Ther. 2018 05 30; 20(1):103.
Methotrexate: who would have predicted its importance in rheumatoid arthritis?
Genovese MC, Weinblatt ME, Aelion JA, Mansikka HT, Peloso PM, Chen K, Li Y, Othman AA, Khatri A, Khan NS, Padley RJ
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study. Arthritis Rheumatol. 2018 11; 70(11):1710-1720.
ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2003 Nov; 48(11):3013-22.
Infections and anti-tumor necrosis factor alpha therapy.
Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M
Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. Arthritis Rheum. 2011 Aug; 63(8):2203-8.
Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity. Curr Opin Rheumatol. 1991 Jun; 3(3):363-8.
Methotrexate: mechanism of action, pharmacokinetics, clinical indications, and toxicity.
Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Irby R, Wolfe F
Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial. Arthritis Rheum. 1990 Mar; 33(3):330-8.
Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial.
Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ, Schiff MH
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001 Jun; 28(6):1238-44.
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
Rheumatoid arthritis. Lancet. 2001 Sep 15; 358(9285):903-11.
Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedrén S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010 Jul; 62(7):1849-61.
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
Journal of the American Academy of Dermatology
Methotrexate in rheumatoid arthritis. J Am Acad Dermatol. 1988 Jul; 19(1 Pt 1):126-8.
Wall BA, Agudelo CA, Weinblatt ME, Turner RA
Acute gout and systemic lupus erythematosus: report of 2 cases and literature review. J Rheumatol. 1982 Mar-Apr; 9(2):305-7.
Acute gout and systemic lupus erythematosus: report of 2 cases and literature review.
Bryant GL, Weinblatt ME, Rumbaugh C, Coblyn JS
Cerebral vasculopathy: an analysis of sixteen cases. Semin Arthritis Rheum. 1986 May; 15(4):297-302.
Cerebral vasculopathy: an analysis of sixteen cases.
Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther. 2011 Jun 08; 13(3):R83.
Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.
Agarwal SK, Maier AL, Chibnik LB, Coblyn JS, Fossel A, Lee R, Fanikos J, Fiumara K, Lowry C, Weinblatt ME
Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum. 2005 Dec 15; 53(6):872-8.
Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center.
Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Dec; 54(12):3790-8.
Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis.
Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, Levin R, Solomon DH
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 2007 Aug 15; 57(6):928-34.
Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal.
Agarwal SK, Glass RJ, Shadick NA, Coblyn JS, Anderson RJ, Maher NE, Weinblatt ME, Solomon DH
Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol. 2008 Sep; 35(9):1737-44.
Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18; 368(9549):1771-81.
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
International journal of clinical practice
Abatacept in the treatment of rheumatoid arthritis. Int J Clin Pract. 2007 Mar; 61(3):494-500.
Abatacept in the treatment of rheumatoid arthritis.
Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis. Rheumatology (Oxford). 2018 11 01; 57(11):1972-1981.
Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis.
Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE
Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28; 312(13):818-22.
Efficacy of low-dose methotrexate in rheumatoid arthritis.
Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, Kim YG, Henry GW, Shadick NA, Weinblatt ME, Lee DM, Rudd PM, Dwek RA
HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem. 2008 May 01; 376(1):1-12.
HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software.
Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung. N Engl J Med. 2009 Apr 23; 360(17):1770-9.
Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung.
Wade SD, Yoshida EM, Carruthers MN, Weinblatt ME
Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate. J Clin Rheumatol. 2021 Jun 01; 27(4):e131-e134.
Transient Elastography for Monitoring for Hepatotoxicity in Rheumatoid Arthritis Patients on Long-term Methotrexate.
Walker AM, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, Lee RG, Weinblatt ME
Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993 Mar; 36(3):329-35.
Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis.
Gravallese EM, Handel ML, Coblyn J, Anderson RJ, Sperling RI, Karlson EW, Maier A, Ruderman EM, Formelli F, Weinblatt ME
N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study. Arthritis Rheum. 1996 Jun; 39(6):1021-6.
N-[4-hydroxyphenyl] retinamide in rheumatoid arthritis: a pilot study.
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, Simon L, Siegel J, Smolen JS, Sokka T, Strand V, Tugwell P, van der Heijde D, van Riel P, Vlad S, van Vollenhoven R, Ward M, Weinblatt M, Wells G, White B, Wolfe F, Zhang B, Zink A, Felson D
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008 Oct; 67(10):1360-4.
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.
Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008 Nov; 58(11):3309-18.
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Journal of pediatric gastroenterology and nutrition
Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. J Pediatr Gastroenterol Nutr. 2009 Sep; 49(3):355-8.
Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease.
Desai SP, Turchin A, Szent-Gyorgyi LE, Weinblatt M, Coblyn J, Solomon DH, Kachalia A
Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality. Rheumatology (Oxford). 2011 Feb; 50(2):366-72.
Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality.
Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, Iannaccone CK, Kvien TK, Haavardsholm EA, Weinblatt ME, Solomon DH
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012 May; 71(5):681-6.
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM
Synovial tissue response to treatment with Campath-1H. Arthritis Rheum. 1995 Feb; 38(2):254-8.
Synovial tissue response to treatment with Campath-1H.
Shadick NA, Fanta CH, Weinblatt ME, O'Donnell W, Coblyn JS
Bronchiectasis. A late feature of severe rheumatoid arthritis. Medicine (Baltimore). 1994 May; 73(3):161-70.
Bronchiectasis. A late feature of severe rheumatoid arthritis.
Weinblatt ME, Fleischmann R, Huizinga TW, Emery P, Pope J, Massarotti EM, van Vollenhoven RF, Wollenhaupt J, Bingham CO, Duncan B, Goel N, Davies OR, Dougados M
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology (Oxford). 2012 Dec; 51(12):2204-14.
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coblyn J, Cui J, Tak PP, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Criswell LA, Amos CI, Seldin MF, Kastner DL, Ardlie KG, Alfredsson L, Costenbader KH, Altshuler D, Huizinga TW, Shadick NA, Weinblatt ME, de Vries N, Worthington J, Seielstad M, Toes RE, Karlson EW, Begovich AB, Klareskog L, Gregersen PK, Daly MJ, Plenge RM
Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008 Oct; 40(10):1216-23.
Common variants at CD40 and other loci confer risk of rheumatoid arthritis.
Ercan A, Cui J, Chatterton DE, Deane KD, Hazen MM, Brintnell W, O'Donnell CI, Derber LA, Weinblatt ME, Shadick NA, Bell DA, Cairns E, Solomon DH, Holers VM, Rudd PM, Lee DM
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010 Aug; 62(8):2239-48.
Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis.
Seminars in cutaneous medicine and surgery
Targeted therapies for psoriatic arthritis: an update for the dermatologist. Semin Cutan Med Surg. 2018 Sep; 37(3):173-181.
Targeted therapies for psoriatic arthritis: an update for the dermatologist.
Total lymphoid irradiation in tertiary care for rheumatoid arthritis. Ann Intern Med. 1985 Apr; 102(4):544-5.
Total lymphoid irradiation in tertiary care for rheumatoid arthritis.
Wall BA, Weinblatt ME, Darnall JT, Muss H
Candida tropicalis arthritis and bursitis. JAMA. 1982 Sep 03; 248(9):1098-9.
Candida tropicalis arthritis and bursitis.
Coblyn JS, Weinblatt M, Holdsworth D, Glass D
Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med. 1981 Aug; 95(2):178-81.
Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients.
Biller J, Asconapé J, Weinblatt ME, Toole JF
Temporal arteritis associated with normal sedimentation rate. JAMA. 1982 Jan 22-29; 247(4):486-7.
Temporal arteritis associated with normal sedimentation rate.
Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. 1995 Nov; 38(11):1589-94.
CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study.
Alemao E, Al MJ, Boonen AA, Stevenson MD, Verstappen SMM, Michaud K, Weinblatt ME, Rutten-van Mölken MPMH
Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLoS One. 2018; 13(10):e0205013.
Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis.
Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis. 2007 Feb; 66(2):228-34.
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy. J Rheumatol. 1994 Jun; 21(6):1144-6.
Tachyphylaxis of intravenous immunoglobulin in refractory inflammatory myopathy.
Methotrexate in rheumatoid arthritis. Bull Rheum Dis. 1993 Jun; 42(4):4-7.
Acquired coagulation inhibitor in association with Rocky Mountain spotted fever. With a review of other acquired coagulation inhibitors. Clin Pediatr (Phila). 1987 Sep; 26(9):459-63.
Acquired coagulation inhibitor in association with Rocky Mountain spotted fever. With a review of other acquired coagulation inhibitors.
Raum D, Awdeh Z, Glass D, Kammer G, Khan MA, Coblyn JS, Weinblatt M, Holdsworth D, Strong L, Rossen RD
Extended haplotypes of chromosome 6 in adult rheumatoid arthritis. Arthritis Rheum. 1984 May; 27(5):516-21.
Extended haplotypes of chromosome 6 in adult rheumatoid arthritis.
Fonseka CY, Rao DA, Teslovich NC, Korsunsky I, Hannes SK, Slowikowski K, Gurish MF, Donlin LT, Lederer JA, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Todd DJ, Bykerk VP, Karlson EW, Ermann J, Lee YC, Brenner MB, Raychaudhuri S
Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis. Sci Transl Med. 2018 10 17; 10(463).
Mixed-effects association of single cells identifies an expanded effector CD4+ T cell subset in rheumatoid arthritis.
DerSimonian H, Sugita M, Glass DN, Maier AL, Weinblatt ME, Rème T, Brenner MB
Clonal V alpha 12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients. J Exp Med. 1993 Jun 01; 177(6):1623-31.
Clonal V alpha 12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients.
Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol. 1996 May; 35(5):403-5.
Methotrexate in rheumatoid arthritis: toxicity issues.
Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME
Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol. 2009 Mar; 36(3):546-51.
Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Solomon DH, Finkelstein JS, Shadick N, LeBoff MS, Winalski CS, Stedman M, Glass R, Brookhart MA, Weinblatt ME, Gravallese EM
The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. Arthritis Rheum. 2009 Jun; 60(6):1624-31.
The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis.
George D, Hoch S, Cohen E, Kantrowitz F, Weinblatt M
Chronic monocytic arthritis. Arthritis Rheum. 1983 May; 26(5):674-7.
Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1995 Nov; 34 Suppl 2:43-8.
Efficacy of methotrexate in rheumatoid arthritis.
Monarticular arthritis: early manifestation of a rhabdomyosarcoma. J Rheumatol. 1981 Jul-Aug; 8(4):685-8.
Monarticular arthritis: early manifestation of a rhabdomyosarcoma.
Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS
Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988 Feb; 31(2):167-75.
Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis.
Scandinavian journal of rheumatology. Supplement
Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly. Scand J Rheumatol Suppl. 1991; 91:9-17.
Nonsteroidal anti-inflammatory drug toxicity: increased risk in the elderly.
Kalra R, Dale D, Freedman M, Bonilla MA, Weinblatt M, Ganser A, Bowman P, Abish S, Priest J, Oseas RS, Olson K, Paderanga D, Shannon K
Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood. 1995 Dec 15; 86(12):4579-86.
Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia.
Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S
Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec; 65(12):1608-12.
Patterns of cardiovascular risk in rheumatoid arthritis.
Weinblatt ME, Fraser PA, Anderson R, Coblyn JS, Trentham DE
Diminution of the T8 subset by amiprilose hydrochloride in refractory RA. J Rheumatol. 1987 Aug; 14(4):859-60.
Diminution of the T8 subset by amiprilose hydrochloride in refractory RA.
Plasmapheresis in the treatment of resistant thrombocytopenia in systemic lupus erythematosus. South Med J. 1982 Oct; 75(10):1277-8.
Plasmapheresis in the treatment of resistant thrombocytopenia in systemic lupus erythematosus.
Rheumatoid arthritis: treat now, not later! Ann Intern Med. 1996 Apr 15; 124(8):773-4.
Rheumatoid arthritis: treat now, not later!
Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME
Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum. 1990 Aug; 33(8):1149-55.
Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate.
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. Arthritis Rheumatol. 2019 06; 71(6):892-900.
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007 Jun; 56(6):1754-64.
Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Johnsen AK, Plenge RM, Butty V, Campbell C, Dieguez-Gonzalez R, Gomez-Reino JJ, Shadick N, Weinblatt M, Gonzalez A, Gregersen PK, Benoist C, Mathis D
A broad analysis of IL1 polymorphism and rheumatoid arthritis. Arthritis Rheum. 2008 Jul; 58(7):1947-57.
A broad analysis of IL1 polymorphism and rheumatoid arthritis.
Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, Catanese JJ, Xie G, Stahl EA, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Burtt NP, Chang M, Coblyn J, Costenbader KH, Criswell LA, Crusius JB, Cui J, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Kurreeman FA, Lee AT, Liu X, Li Y, Martin P, Morgan AW, Padyukov L, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth P, Altshuler D, Karlson EW, Toes RE, de Vries N, Begovich AB, Siminovitch KA, Worthington J, Klareskog L, Gregersen PK, Daly MJ, Plenge RM
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet. 2009 Dec; 41(12):1313-8.
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk.
Gravallese EM, Corson JM, Coblyn JS, Pinkus GS, Weinblatt ME
Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore). 1989 Mar; 68(2):95-106.
Rheumatoid aortitis: a rarely recognized but clinically significant entity.
[A 31-year-old asthmatic woman with multisystemic disease]. Medicina (Firenze). 1988 Oct-Dec; 8(4):465-72.
[A 31-year-old asthmatic woman with multisystemic disease].
Curtis JR, Flake DD, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019 05 01; 58(5):874-883.
Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.
Kremer JM, Alarcón GS, Lightfoot RW, Willkens RF, Furst DE, Williams HJ, Dent PB, Weinblatt ME
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar; 37(3):316-28.
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.
Katz JN, Wright EA, Lynch KD, Weinblatt ME
Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Arthritis Rheum. 1996 Jan; 39(1):177-8.
Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis.
Shadick NA, Heller JE, Weinblatt ME, Maher NE, Cui J, Ginsburg G, Coblyn J, Anderson R, Solomon DH, Roubenoff R, Parker A
Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis. Ann Rheum Dis. 2007 Nov; 66(11):1497-502.
Opposing effects of the D70 mutation and the shared epitope in HLA-DR4 on disease activity and certain disease phenotypes in rheumatoid arthritis.
Arthritis care and research : the official journal of the Arthritis Health Professions Association
Treatment of rheumatoid arthritis. Arthritis Care Res. 1989 Sep; 2(3):S23-32.
Spragg J, Coblyn JS, Fraser PA, Austen KF, Weinblatt ME
Advances in experimental medicine and biology
The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis. Adv Exp Med Biol. 1989; 247A:389-92.
The effect of cyclosporine on urinary kallikrein excretion in patients with rheumatoid arthritis.
Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis. Clin Exp Rheumatol. 2010 Sep-Oct; 28(5 Suppl 61):S9-12.
Clinical trials to establish methotrexate as a therapy for rheumatoid arthritis.
Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, Izmailova ES, Roubenoff R, Shadick NA, Weinblatt ME, Centola M, Lee DM
Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum. 2011 Apr; 63(4):894-903.
Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor.
Liao KP, Weinblatt ME, Cui J, Iannaccone C, Chibnik LB, Lu B, Coblyn JS, Shadick NA, Solomon DH
Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study. Rheumatology (Oxford). 2011 Aug; 50(8):1473-9.
Clinical predictors of erosion-free status in rheumatoid arthritis: a prospective cohort study.
Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019 07; 71(7):1042-1055.
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis.
Lillegraven S, Paynter N, Prince FH, Shadick NA, Haavardsholm EA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH
Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Apr; 65(4):526-33.
Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritis.
Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl. 1985 Dec; 12 Suppl 12:35-9.
Toxicity of low dose methotrexate in rheumatoid arthritis.
Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis. 2019 07; 78(7):872-878.
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.
Sparks JA, Doyle TJ, He X, Pan B, Iannaccone C, Frits ML, Dellaripa PF, Rosas IO, Lu B, Weinblatt ME, Shadick NA, Karlson EW
Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis. ACR Open Rheumatol. 2019 Mar; 1(1):4-15.
Incidence and predictors of dyspnea on exertion in a prospective cohort of patients with rheumatoid arthritis.
Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, Gill RR, Hatabu H, Nishino M, Murphy DJ, Iannaccone CK, Mahmoud TG, Frits ML, Lu B, Rosas IO, Dellaripa PF, Weinblatt ME, Karlson EW, Shadick NA, Doyle TJ
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis Rheumatol. 2019 09; 71(9):1472-1482.
Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study.
Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC
Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS One. 2019; 14(4):e0214981.
Prevalence and predictors for sustained remission in rheumatoid arthritis.
Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept. Ann Rheum Dis. 2019 09; 78(9):1285-1286.
Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
Bay-Jensen AC, Platt A, Jenkins MA, Weinblatt ME, Byrjalsen I, Musa K, Genovese MC, Karsdal MA
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatol. 2019; 3:3.
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis.
Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Ann Rheum Dis. 2019 08; 78(8):1055-1061.
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.
Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney. Kidney Int Rep. 2019 May; 4(5):745-748.
Rheumatoid Nodule Formation in the Kidney: A Diagnosis of Exclusion and a Rare Manifestation of Rheumatoid Arthritis Involving the Kidney.
Alemao E, Iannaccone CK, Weinblatt ME, Shadick NA
Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a US Observational Cohort. Clin Ther. 2019 06; 41(6):1057-1065.e3.
Association of Changes in Anticitrullinated Protein Antibody Levels With Resource Use and Disease Activity Measures in Rheumatoid Arthritis Patients a US Observational Cohort.
Mahmoud TG, Huang J, Frits M, Iannaccone C, Bykerk V, Bingham CO, Weinblatt M, Shadick NA
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change. J Rheumatol. 2020 03; 47(3):333-340.
Correlates of Successful Rheumatoid Arthritis Flare Management: Clinician-driven Treatment, Home-based Strategies, and Medication Change.
Yang N, Huang J, Frits M, Iannaccone C, Weinblatt ME, Rifai N, Shadick N, Bradwin G, Liao KP
Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis. Pract Lab Med. 2019 Aug; 16:e00122.
Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis.
In Memoriam: Shaun Ruddy, MD, 1935-2019. Arthritis Rheumatol. 2019 Aug; 71(8):1215-1216.
In Memoriam: Shaun Ruddy, MD, 1935-2019.
Shadick NA, Gerlanc NM, Frits ML, Stolshek BS, Brady BL, Iannaccone C, Collier D, Cui J, Mutebi A, Weinblatt ME
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry. Clin Rheumatol. 2019 Nov; 38(11):3081-3092.
The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Huang S, He X, Doyle TJ, Zaccardelli A, Marshall AA, Friedlander HM, Blaustein RB, Smith EA, Cui J, Iannaccone CK, Mahmoud TG, Weinblatt ME, Dellaripa PF, Shadick NA, Sparks JA
Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clin Rheumatol. 2019 12; 38(12):3401-3412.
Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS One. 2019; 14(8):e0221314.
Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis.
Alemao E, Bao Y, Weinblatt ME, Shadick N
Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. Arthritis Care Res (Hoboken). 2020 02; 72(2):176-183.
Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
Traylor M, Knevel R, Cui J, Taylor J, Harm-Jan W, Conaghan PG, Cope AP, Curtis C, Emery P, Newhouse S, Patel H, Steer S, Gregersen P, Shadick NA, Weinblatt ME, Van Der Helm-van Mil A, Barrett JH, Morgan AW, Lewis CM, Scott IC
Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. PLoS One. 2019; 14(10):e0223246.
Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.
Craft JE, Crow MK, Lockshin MD, Salmon JE, Diamond B, Elkon KB, Flood J, Fox DA, Gabriel SE, Gilkeson GS, Hahn BH, Hardin J, Koopman WJ, Seaman WE, Wofsy D, Sergent JS, Uknis AB, Weinblatt ME
Georgia Abortion Law and Our Commitment to Patients. Arthritis Rheumatol. 2020 02; 72(2):377-378.
Georgia Abortion Law and Our Commitment to Patients.
Fleischmann R, Weinblatt M, Ahmad H, Maldonado MA, Alemao E, Ye J, Schiff M
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE). Rheumatol Ther. 2019 Dec; 6(4):559-571.
Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE).
Winthrop KL, Weinblatt ME, Bathon J, Burmester GR, Mease PJ, Crofford L, Bykerk V, Dougados M, Rosenbaum JT, Mariette X, Sieper J, Melchers F, Cronstein BN, Breedveld FC, Kalden J, Smolen JS, Furst D
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis. 2020 01; 79(1):88-93.
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.
Feldman CH, Yoshida K, Xu C, Frits ML, Shadick NA, Weinblatt ME, Connolly SE, Alemao E, Solomon DH
Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. ACR Open Rheumatol. 2019 Nov; 1(9):552-559.
Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach.
Shadick NA, Katz P, Iannaccone CI, Maica G, Coblyn J, Weinblatt ME, Cui J
The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study. ACR Open Rheumatol. 2019 Dec; 1(10):620-626.
The Impact of Exercise, Lifestyle, and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study.
Smolen JS, Choe JY, Weinblatt ME, Emery P, Keystone E, Genovese MC, Myung G, Hong E, Baek I, Ghil J
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis. RMD Open. 2020 01; 6(1).
Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.
Correction to: Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry. Clin Rheumatol. 2020 04; 39(4):1371-1372.
Correction to: Association of rheumatoid arthritis-related autoantibodies with pulmonary function test abnormalities in a rheumatoid arthritis registry.
Windebank KP, Tefferi A, Smithson WA, Li CY, Solberg LA, Priest JR, Elliott SC, de Alarcon PA, Weinblatt ME, Burgert EO
Acute megakaryocytic leukemia (M7) in children. Mayo Clin Proc. 1989 Nov; 64(11):1339-51.
Acute megakaryocytic leukemia (M7) in children.
Weinblatt ME, Ortega JA, Giggins GR, Siegel SE
Dianhydrogalactitol in the treatment of children with primary brain tumors. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):923-4.
Dianhydrogalactitol in the treatment of children with primary brain tumors.
Weinblatt M, Petrikovsky B, Bialer M, Kochen J, Harper R
Prenatal evaluation and in utero platelet transfusion for thrombocytopenia absent radii syndrome. Prenat Diagn. 1994 Sep; 14(9):892-6.
Prenatal evaluation and in utero platelet transfusion for thrombocytopenia absent radii syndrome.
Weinblatt ME, Ortega JA, Miller JH, Fishman LS
The American journal of pediatric hematology/oncology
The reliability of noninvasive diagnostic procedures in children with brain tumors. Am J Pediatr Hematol Oncol. 1982; 4(4):367-73.
The reliability of noninvasive diagnostic procedures in children with brain tumors.
The Pediatric infectious disease journal
Stomatococcus mucilaginosus infections in children with leukemia. Pediatr Infect Dis J. 1990 Sep; 9(9):678-9.
Stomatococcus mucilaginosus infections in children with leukemia.
Annals of clinical and laboratory science
Chronically transfused patients with increased hemoglobin Alc secondary to donor blood. Ann Clin Lab Sci. 1986 Jan-Feb; 16(1):34-7.
Chronically transfused patients with increased hemoglobin Alc secondary to donor blood.
Aplastic anemia in Down's syndrome. Pediatrics. 1981 Jun; 67(6):896-7.
Scimeca PG, Weinblatt ME, Slepowitz G, Harper RG, Kochen JA
Diamond-Blackfan syndrome: an unusual cause of hydrops fetalis. Am J Pediatr Hematol Oncol. 1988; 10(3):241-3.
Diamond-Blackfan syndrome: an unusual cause of hydrops fetalis.
Treatment of children with dysgerminoma of the ovary. Cancer. 1982 Jun 15; 49(12):2608-11.
Treatment of children with dysgerminoma of the ovary.
Paraplegia in children with malignant teratoma. Cancer. 1985 Oct 15; 56(8):2140-2.
Paraplegia in children with malignant teratoma.
Weinblatt ME, Scimeca PG, James-Herry AG, Pahwa S
American journal of diseases of children (1960)
Thrombocytopenia in an infant with AIDS. Am J Dis Child. 1987 Jan; 141(1):15.
Thrombocytopenia in an infant with AIDS.
Steroid responsiveness. A predictor of the outcome of splenectomy in children with chronic immune thrombocytopenic purpura. Am J Dis Child. 1982 Dec; 136(12):1064-6.
Steroid responsiveness. A predictor of the outcome of splenectomy in children with chronic immune thrombocytopenic purpura.
How dangerous are blood transfusions in 'premies'? Pediatrics. 1984 Apr; 73(4):569-70.
How dangerous are blood transfusions in 'premies'?
Hemolysis after treatment with ceftriaxone. J Pediatr. 1996 Jan; 128(1):163.
Hemolysis after treatment with ceftriaxone.
Scimeca PG, Weinblatt ME, Schonfeld G, Kaplan MH, Kochen JH
Babesiosis in two infants from Eastern Long Island, NY. Am J Dis Child. 1986 Oct; 140(10):971.
Babesiosis in two infants from Eastern Long Island, NY.
Hypertension in children with neurogenic tumors. Pediatrics. 1983 Jun; 71(6):947-51.
Hypertension in children with neurogenic tumors.
Screening for neuroblastoma. Pediatrics. 1988 Jan; 81(1):175-7.
Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME
Journal of pediatric hematology/oncology
Chemotherapeutic treatment of malignant chordoma in children. J Pediatr Hematol Oncol. 1996 May; 18(2):237-40.
Chemotherapeutic treatment of malignant chordoma in children.
Weinblatt ME, Fort P, Kochen J, DiMayio M
Polycythemia in hypothyroid infants. Am J Dis Child. 1987 Oct; 141(10):1121-3.
Rhabdoid tumor of the central nervous system. Med Pediatr Oncol. 1992; 20(3):258.
Rhabdoid tumor of the central nervous system.
Morphologic changes in blast cells of children with acute lymphoblastic leukemia in relapse. Med Pediatr Oncol. 1983; 11(5):339-42.
Morphologic changes in blast cells of children with acute lymphoblastic leukemia in relapse.
Hemangioendothelioma with intravascular coagulation and ischemic colitis. Cancer. 1984 Nov 15; 54(10):2300-4.
Hemangioendothelioma with intravascular coagulation and ischemic colitis.
Radionuclide scanning in children with rhabdomyosarcoma. Med Pediatr Oncol. 1981; 9(3):293-301.
Radionuclide scanning in children with rhabdomyosarcoma.
Miller JH, Weinblatt ME, Smith JC, Fishman LS, Segall HD, Ortega JA
Combined computed tomographic and radionuclide imaging in the long-term follow-up of children with primary intra-axial intracranial neoplasms. Radiology. 1983 Mar; 146(3):681-6.
Combined computed tomographic and radionuclide imaging in the long-term follow-up of children with primary intra-axial intracranial neoplasms.
Thrombocytopenia and pediatric patients with AIDS. Pediatrics. 1989 Aug; 84(2):401-2.
Thrombocytopenia and pediatric patients with AIDS.
Weinblatt ME, Siegel SE, Siegel MM, Stanley P, Weitzman JJ
Preoperative chemotherapy for unresectable primary hepatic malignancies in children. Cancer. 1982 Sep 15; 50(6):1061-4.
Preoperative chemotherapy for unresectable primary hepatic malignancies in children.
Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, Chatham W, Cohen S, Costenbader K, Gravallese EM, Kalil AC, Weinblatt ME, Winthrop K, Mudano AS, Turner A, Saag KG
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol. 2020 08; 72(8):1241-1251.
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Stevens E, Weinblatt ME, Massarotti E, Griffin F, Emani S, Desai S
Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients. ACR Open Rheumatol. 2020 Jun; 2(6):357-361.
Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients.
Emery P, Suh CH, Weinblatt ME, Smolen JS, Keystone EC, Genovese M, Vencovsky J, Kay J, Hong E, Baek Y, Ghil J
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis. Scand J Rheumatol. 2020 Sep; 49(5):361-370.
Impact of immunogenicity on efficacy and tolerability of tumour necrosis factor inhibitors: pooled analysis of biosimilar studies in rheumatoid arthritis.
Degboé Y, Schiff M, Weinblatt M, Fleischmann R, Ahmad HA, Constantin A
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis. J Clin Med. 2020 Jun 26; 9(6).
Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis.
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2020 09; 72(9):e1-e12.
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2.
Smolen JS, Kang YM, Yoo WH, Emery P, Weinblatt ME, Keystone EC, Genovese MC, Myung G, Baek I, Ghil J
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis. Arthritis Res Ther. 2020 08 14; 22(1):188.
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.
Valerio V, Kwok M, Loewen H, Winkler J, Mody GM, Scuccimarri R, Meltzer M, Mengistu Y, Feldman CH, Weinblatt ME, Lacaille D, Hitchon CA, Colmegna I
Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clin Rheumatol. 2021 Apr; 40(4):1259-1271.
Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis.
Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). J Rheumatol. 2021 05; 48(5):767-774.
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR).
Curtis JR, Weinblatt M, Saag K, Bykerk VP, Furst DE, Fiore S, St John G, Kimura T, Zheng S, Bingham CO, Wright G, Bergman M, Nola K, Charles-Schoeman C, Shadick N
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. Arthritis Care Res (Hoboken). 2021 04; 73(4):471-480.
Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry.
Huang S, Doyle TJ, Hammer MM, Byrne SC, Huang W, Marshall AA, Iannaccone CK, Huang J, Feathers V, Weinblatt ME, Dellaripa PF, Shadick NA, Sparks JA
Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. Semin Arthritis Rheum. 2020 12; 50(6):1216-1225.
Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality.
Kronzer VL, Huang W, Dellaripa PF, Huang S, Feathers V, Lu B, Iannaccone CK, Gill RR, Hatabu H, Nishino M, Crowson CS, Davis JM, Weinblatt ME, Shadick NA, Doyle TJ, Sparks JA
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease. J Rheumatol. 2021 05; 48(5):656-663.
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-associated Interstitial Lung Disease.
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2021 02; 73(2):e1-e12.
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3.
Kremer JM, Pappas DA, Kane K, Greenberg J, Harrold LR, Feathers VL, Shadick N, Weinblatt ME, Reed G
The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies. J Rheumatol. 2021 12; 48(12):1776-1783.
The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies.
Curtis JR, Weinblatt ME, Shadick NA, Brahe CH, Østergaard M, Hetland ML, Saevarsdottir S, Horton M, Mabey B, Flake DD, Ben-Shachar R, Sasso EH, Huizinga TW
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. Arthritis Res Ther. 2021 01 04; 23(1):1.
Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies.
Weber B, He Z, Yang N, Playford MP, Weisenfeld D, Iannaccone C, Coblyn J, Weinblatt M, Shadick N, Di Carli M, Mehta NN, Plutzky J, Liao KP
Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation. Arthritis Rheumatol. 2021 06; 73(6):970-979.
Divergence of Cardiovascular Biomarkers of Lipids and Subclinical Myocardial Injury Among Rheumatoid Arthritis Patients With Increased Inflammation.
Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2021 12 24; 61(1):121-130.
Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study.
Niaki OZ, Penn E, Scott DA, Cobos G, Vleugels RA, Weinblatt ME
Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib. JAMA Dermatol. 2021 06 01; 157(6):735-737.
Treatment of Severe Multicentric Reticulohistiocytosis With Upadacitinib.
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021 07; 73(7):1108-1123.
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 07; 73(7):924-939.
Hitchon CA, Mody GM, Feldman CH, Lau Y, Shi S, Meltzer M, Scuccimarri R, Weinblatt ME, Colmegna I
Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study. ACR Open Rheumatol. 2021 Aug; 3(8):522-530.
Perceptions and Challenges Experienced by African Physicians When Prescribing Methotrexate for Rheumatic Disease: An Exploratory Study.
Pierson SK, Shenoy S, Oromendia AB, Gorzewski AM, Langan Pai RA, Nabel CS, Ruth JR, Parente SAT, Arenas DJ, Guilfoyle M, Reddy M, Weinblatt M, Shadick N, Bower M, Pria AD, Masaki Y, Katz L, Mezey J, Beineke P, Lee D, Tendler C, Kambayashi T, Fosså A, van Rhee F, Fajgenbaum DC
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. Blood Adv. 2021 09 14; 5(17):3445-3456.
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Kremer JM, Reed G, Pappas DA, Kane K, Feathers VL, Weinblatt ME, Shadick N, Greenberg J, Harrold LL
Dr. Kremer et al reply. J Rheumatol. 2022 03; 49(3):338-339.
He M, Pawar A, Desai RJ, Glynn RJ, Lee H, Weinblatt ME, Solomon DH, Kim SC
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study. Semin Arthritis Rheum. 2021 12; 51(6):1242-1250.
Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study.
Esposito AJ, Sparks JA, Gill RR, Hatabu H, Schmidlin EJ, Hota PV, Poli S, Fletcher EA, Xiong W, Frits ML, Iannaccone CK, Prado M, Zaccardelli A, Marshall A, Dellaripa PF, Weinblatt ME, Shadick NA, Rosas IO, Doyle TJ
Screening for preclinical parenchymal lung disease in rheumatoid arthritis. Rheumatology (Oxford). 2022 08 03; 61(8):3234-3245.
Screening for preclinical parenchymal lung disease in rheumatoid arthritis.
Jabado O, Maldonado MA, Schiff M, Weinblatt ME, Fleischmann R, Robinson WH, He A, Patel V, Greenfield A, Saini J, Galbraith D, Connolly SE
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. Rheumatol Ther. 2022 Apr; 9(2):391-409.
Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis.
Zhuo J, Xia Q, Sharma N, Gao S, Lama S, Cui J, Feathers V, Shadick N, Weinblatt ME
The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity. Rheumatol Ther. 2022 Apr; 9(2):637-647.
The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity.
Lee H, Chen SK, Gautam N, Vine SM, He M, Desai RJ, Weinblatt ME, Glynn RJ, Kim SC
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. Clin Exp Rheumatol. 2023 Jan; 41(1):110-117.
Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study.
D'Andrea E, Desai RJ, He M, Glynn RJ, Lee H, Weinblatt ME, Kim SC
Journal of the American College of Cardiology
Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis. J Am Coll Cardiol. 2022 07 05; 80(1):36-46.
Cardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis.
Kawano Y, Patel NJ, Wang X, Cook CE, Vanni KM, Kowalski EN, Banasiak EP, Qian G, DiIorio M, Hsu TY, Weinblatt ME, Todd DJ, Wallace ZS, Sparks JA
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. Ann Rheum Dis. 2022 12; 81(12):1742-1749.
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
Kawano Y, Patel NJ, Wang X, Cook CE, Vanni KMM, Kowalski EN, Banasiak EP, Qian G, DiIorio M, Hsu TYT, Weinblatt ME, Todd DJ, Wallace ZS, Sparks JA
medRxiv : the preprint server for health sciences
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron. medRxiv. 2022 Jun 20.
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron.
Felson D, Feathers V, Naik C, Solomon DH, Weinblatt ME, Shadick N
Meaning of patient global assessment when joint counts are low in rheumatoid arthritis. RMD Open. 2022 06; 8(2).
Meaning of patient global assessment when joint counts are low in rheumatoid arthritis.
Wu X, Jeong Y, Poli de Frías S, Easthausen I, Hoffman K, Oromendia C, Taheri S, Esposito AJ, Quesada Arias L, Ayaub EA, Maurer R, Gill RR, Hatabu H, Nishino M, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Dellaripa PF, Choi AMK, Kim EY, Rosas IO, Martinez FJ, Doyle TJ
Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis. Thorax. 2022 10; 77(10):1041-1044.
Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis.
Qian G, Wang X, Patel NJ, Kawano Y, Fu X, Cook CE, Vanni KMM, Kowalski EN, Banasiak EP, Bade KJ, Srivatsan S, Williams ZK, Todd DJ, Weinblatt ME, Wallace ZS, Sparks JA
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study. medRxiv. 2022 Oct 30.
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
From Canadian Living Guidelines to Global Living Guidelines: A Post Pandemic Effort. J Rheumatol. 2022 10; 49(10):1077-1078.
From Canadian Living Guidelines to Global Living Guidelines: A Post Pandemic Effort.
Botson JK, Saag K, Peterson J, Parikh N, Ong S, La D, LoCicero K, Obermeyer K, Xin Y, Chamberlain J, LaMoreaux B, Verma S, Sainati S, Grewal S, Majjhoo A, Tesser JRP, Weinblatt ME
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings. Arthritis Rheumatol. 2023 02; 75(2):293-304.
A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, Song Y, LaMoreaux B, Zhao L, Xin Y, Chamberlain J, Ramanathan S, Weinblatt ME, Peterson J
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Arthritis Res Ther. 2022 08 25; 24(1):208.
A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
Amaral JK, Bingham CO, Taylor PC, Vilá LM, Weinblatt ME, Schoen RT
Pathogenesis of chronic chikungunya arthritis: Resemblances and links with rheumatoid arthritis. Travel Med Infect Dis. 2023 Mar-Apr; 52:102534.
Pathogenesis of chronic chikungunya arthritis: Resemblances and links with rheumatoid arthritis.
Botson JK, Obermeyer K, LaMoreaux B, Zhao L, Weinblatt ME, Peterson J
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial. Arthritis Res Ther. 2022 12 27; 24(1):281.
Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
Whelan MG, Santacroce L, Masto L, Qian G, Kowalski E, Vanni K, Kanjilal S, Weinblatt ME, Sparks JA, Tedeschi SK
Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination. Clin Rheumatol. 2023 Jun; 42(6):1695-1700.
Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination.
Taylor PC, Chen YF, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther. 2023 Apr; 10(2):463-476.
Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.
Maica GL, Iannaccone C, Feathers V, Frits ML, Bykerk VP, Bingham CO, Weinblatt M, Shadick NA
Understanding Differences in Patient Descriptions of Rheumatoid Arthritis Flares Using OMERACT Core Domains. J Rheumatol. 2023 07; 50(7):889-894.
Understanding Differences in Patient Descriptions of Rheumatoid Arthritis Flares Using OMERACT Core Domains.
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study. Lancet Rheumatol. 2023 Mar; 5(3):e139-e150.
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study.
Kronzer VL, Hayashi K, Yoshida K, Davis JM, McDermott GC, Huang W, Dellaripa PF, Cui J, Feathers V, Gill RR, Hatabu H, Nishino M, Blaustein R, Crowson CS, Robinson WH, Sokolove J, Liao KP, Weinblatt ME, Shadick NA, Doyle TJ, Sparks JA
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study. Lancet Rheumatol. 2023 Feb; 5(2):e77-e87.
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study.
Das P, Weisenfeld D, Dahal K, De D, Feathers V, Coblyn JS, Weinblatt ME, Shadick NA, Cai T, Liao KP
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis. Arthritis Res Ther. 2023 06 02; 25(1):93.
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis.
Anderson RJ, Cui J, Weinblatt ME, Solomon DH, Naik C, Shadick NA
Patterns of Involvement of the Hand Joints in Classical Rheumatoid Arthritis. J Clin Rheumatol. 2023 Aug 01; 29(5):230-234.
Patterns of Involvement of the Hand Joints in Classical Rheumatoid Arthritis.
Shadick N, Hagino O, Praestgaard A, Fiore S, Weinblatt M, Burmester G
Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry. Arthritis Res Ther. 2023 05 27; 25(1):88.
Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry.
Botson JK, Saag K, Peterson J, Obermeyer K, Xin Y, LaMoreaux B, Padnick-Silver L, Verma S, Grewal S, Majjhoo A, Tesser JRP, Weinblatt ME
A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings. ACR Open Rheumatol. 2023 Aug; 5(8):407-418.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings.
Fleischmann RM, van der Heijde D, Strand V, Atsumi T, McInnes IB, Takeuchi T, Taylor PC, Bracher M, Brooks D, Davies J, Goode C, Gupta A, Mukherjee S, O'Shea C, Saurigny D, Schifano LA, Shelton C, Smith JE, Wang M, Wang R, Watts S, Weinblatt ME
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Ann Rheum Dis. 2023 12; 82(12):1516-1526.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Amaral JK, Taylor PC, Weinblatt ME, Bandeira Í, Schoen RT
Quality of Life and Disability in Chikungunya Arthritis. Curr Rheumatol Rev. 2024; 20(1):65-71.
Quality of Life and Disability in Chikungunya Arthritis.
Taylor PC, Weinblatt ME, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Davies J, Goode C, Gupta A, Mukherjee S, O'Shea C, Saurigny D, Schifano LA, Shelton C, Smith JE, Wang M, Wang R, Watts S, Fleischmann RM
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3). Ann Rheum Dis. 2023 12; 82(12):1527-1537.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
The American journal of tropical medicine and hygiene
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients. Am J Trop Med Hyg. 2023 09 06; 109(3):542-547.
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients.
Doyle TJ, Juge PA, Peljto AL, Lee S, Walts AD, Esposito AJ, Poli S, Gill R, Hatabu H, Nishino M, Dellaripa PF, Weinblatt ME, Shadick NA, Demoruelle MK, Sparks JA, Rosas IO, Granger B, Deane KD, Crestani B, Wolters PJ, Dieudé P, Lee JS
Short peripheral blood leukocyte telomere length in rheumatoid arthritis-interstitial lung disease. Thorax. 2024 01 18; 79(2):182-185.
Short peripheral blood leukocyte telomere length in rheumatoid arthritis-interstitial lung disease.
Zhang X, Xia J, Jiang Y, Pisetsky DS, Smolen JS, Mu R, Dai S, Weinblatt ME, Kvien TK, Li J, Dörner T, Zhang Y, Lu L, Yang C, Yang P, Zhang Y, Xu C, Zhao Z, Lipsky PE
2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis. J Autoimmun. 2024 Jan; 142:103148.
2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis.
McDermott GC, DiIorio M, Kawano Y, Jeffway M, MacVicar M, Dahal K, Moon SJ, Seyok T, Coblyn J, Massarotti E, Weinblatt ME, Weisenfeld D, Liao KP
Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024 06; 66:152421.
Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
Weber B, Weisenfeld D, Massarotti E, Seyok T, Cremone G, Lam E, Golnik C, Brownmiller S, Liu F, Huang S, Todd DJ, Coblyn JS, Weinblatt ME, Cai T, Dahal K, Kohler M, Yinh J, Barrett L, Solomon DH, Plutzky J, Schelbert HR, Campisi R, Bolster MB, Di Carli M, Liao KP
Journal of the American Heart Association
Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study. J Am Heart Assoc. 2024 May 07; 13(9):e030387.
Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study.
Paudel ML, Li R, Naik C, Shadick N, Weinblatt ME, Solomon DH
Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry. Rheumatology (Oxford). 2025 03 01; 64(3):1102-1110.
Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient registry.
Venkat RK, Hayashi K, Juge PA, McDermott G, Paudel M, Wang X, Vanni KMM, Kowalski EN, Qian G, Bade KJ, Saavedra AA, Mueller KT, Chang SH, Dellaripa PF, Weinblatt ME, Shadick NA, Doyle TJ, Dieude P, Sparks JA
Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease. Clin Rheumatol. 2024 Aug; 43(8):2453-2466.
Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease.
Weber BN, Weisenfeld D, Jeffway M, Liu F, McDermott G, Coblyn J, Weinblatt ME, Shadick N, Di Carli M, Liao KP
The Association Between High-Sensitivity Cardiac Troponin T and Major Adverse Cardiovascular Events in Rheumatoid Arthritis. J Rheumatol. 2024 Sep 01; 51(9):942-944.
The Association Between High-Sensitivity Cardiac Troponin T and Major Adverse Cardiovascular Events in Rheumatoid Arthritis.
McDermott GC, Hayashi K, Juge PA, Gill R, Byrne S, Gagne S, Wang X, Paudel ML, Moll M, Cho MH, Vanni K, Kowalski E, Qian G, Bade K, Saavedra A, Kawano Y, DiIorio M, Wolfgang T, Kim EY, Dellaripa PF, Weinblatt ME, Shadick N, Doyle TJ, Sparks JA
Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes. Arthritis Care Res (Hoboken). 2025 Feb; 77(2):185-194.
Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-Associated Interstitial Lung Disease Subtypes.
Smolen JS, Taylor PC, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, Lauwerys B, Tilt N, Ufuktepe B, Xavier RM, Balsa A, Curtis JR, Mikuls TR, Weinblatt M
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2024 11 01; 63(11):3015-3024.
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.
Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, Pappu R, Delaet I, Luo A, Gujrathi S, Hochberg MC
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013 Jun; 40(6):787-97.
Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
Dervieux T, Weinblatt ME, Kivitz A, Kremer JM
Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis. Ann Rheum Dis. 2013 Jun; 72(6):908-10.
Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis.
Iannaccone CK, Fossel A, Tsao H, Cui J, Weinblatt M, Shadick N
Factors associated with attrition in a longitudinal rheumatoid arthritis registry. Arthritis Care Res (Hoboken). 2013 Jul; 65(7):1183-9.
Factors associated with attrition in a longitudinal rheumatoid arthritis registry.
Centola M, Cavet G, Shen Y, Ramanujan S, Knowlton N, Swan KA, Turner M, Sutton C, Smith DR, Haney DJ, Chernoff D, Hesterberg LK, Carulli JP, Taylor PC, Shadick NA, Weinblatt ME, Curtis JR
Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013; 8(4):e60635.
Development of a multi-biomarker disease activity test for rheumatoid arthritis.
Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis. 2013 Sep 01; 72(9):1445-52.
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis.
Transactions of the American Clinical and Climatological Association
Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc. 2013; 124:16-25.
Methotrexate in rheumatoid arthritis: a quarter century of development.
Tirumani SH, Ramaiya NH, Weinblatt ME, Leibner HA, Creager MA, LaCasce AS
Large vessel vasculopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Jul; 55(7):1654-6.
Large vessel vasculopathy in Epstein-Barr virus-positive diffuse large B-cell lymphoma.
Botson J, Obermeyer K, LaMoreaux B, Padnick-Silver L, Verma S, Weinblatt ME, Peterson J
Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings. Rheumatol Adv Pract. 2024; 8(4):rkae145.
Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings.
Longley MJ, Gaffney RG, Smith JS, DeSimone MS, Weinblatt ME, Merola JF
VEXAS in a patient with hypereosinophilia and Sweet's-like lesions. JAAD Case Rep. 2024 Nov; 53:71-74.
VEXAS in a patient with hypereosinophilia and Sweet's-like lesions.
Lin C, Karlson EW, Canhao H, Miller TA, Dligach D, Chen PJ, Perez RN, Shen Y, Weinblatt ME, Shadick NA, Plenge RM, Savova GK
Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records. PLoS One. 2013; 8(8):e69932.
Automatic prediction of rheumatoid arthritis disease activity from the electronic medical records.
Shimizu M, Paudel ML, Shadick N, Weinblatt M, Solomon DH
Age of onset of rheumatoid arthritis and radiographic changes. Semin Arthritis Rheum. 2025 04; 71:152635.
Age of onset of rheumatoid arthritis and radiographic changes.
Amaral JK, Schoen RT, Weinblatt ME, Cândido EL
Tropical medicine and infectious disease
Chikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2025 Feb 12; 10(2).
Chikungunya Fever and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Yoshida K, Radner H, Kavanaugh A, Sung YK, Bae SC, Kishimoto M, Matsui K, Okada M, Tohma S, Weinblatt ME, Solomon DH
Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clin Exp Rheumatol. 2013 Jul-Aug; 31(4 Suppl 78):S28-32.
Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, Nishino M, Weinblatt ME, Ascherman DP, Washko GR, Hunninghake GM, Choi AMK, Shadick NA, Rosas IO
Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014 Jul; 146(1):41-50.
Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis.
Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Curtis P, Gupta A, Nijhawan R, O'Shea C, Rayner K, Saurigny D, Shelton C, Wang M, Wang R, Fleischmann RM
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open. 2025 Mar 05; 15(3):e088869.
Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).
Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014 Jan; 73(1):86-94.
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Yoshida K, Sung YK, Kavanaugh A, Bae SC, Weinblatt ME, Kishimoto M, Matsui K, Tohma S, Solomon DH
Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al. Ann Rheum Dis. 2014 Jan; 73(1):e5.
Response to: 'Biologic discontinuation studies: a systematic review of methods' by van der Maas et al.
Cui J, Taylor KE, Lee YC, Källberg H, Weinblatt ME, Coblyn JS, Klareskog L, Criswell LA, Gregersen PK, Shadick NA, Plenge RM, Karlson EW
The influence of polygenic risk scores on heritability of anti-CCP level in RA. Genes Immun. 2014 Mar; 15(2):107-14.
The influence of polygenic risk scores on heritability of anti-CCP level in RA.
Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis. 2014 Mar; 73(3):595-9.
Biologic discontinuation studies: a systematic review of methods.
Lee YC, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Williams DA, Cui J
Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheumatol. 2014 Aug; 66(8):2006-14.
Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors.
Weinblatt ME, Kahn E, Scimeca PG, Kochen JA
Hemolytic uremic syndrome associated with cisplatin therapy. Am J Pediatr Hematol Oncol. 1987; 9(4):295-8.
Hemolytic uremic syndrome associated with cisplatin therapy.
Danazol for children with immune thrombocytopenic purpura. Am J Dis Child. 1988 Dec; 142(12):1317-9.
Danazol for children with immune thrombocytopenic purpura.
Drachtman R, Weinblatt M, Sitarz A, Gold A, Kochen J
Marrow hypoplasia associated with congenital neurologic anomalies in two siblings. Acta Paediatr Scand. 1990 Oct; 79(10):990-3.
Marrow hypoplasia associated with congenital neurologic anomalies in two siblings.
Renal cell carcinoma in patients with tuberous sclerosis. Pediatrics. 1987 Dec; 80(6):898-903.
Renal cell carcinoma in patients with tuberous sclerosis.
Bykerk VP, Shadick N, Frits M, Bingham CO, Jeffery I, Iannaccone C, Weinblatt M, Solomon DH
Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry. J Rheumatol. 2014 Feb; 41(2):227-34.
Flares in rheumatoid arthritis: frequency and management. A report from the BRASS registry.
Bingham CO, Weinblatt M, Han C, Gathany TA, Kim L, Lo KH, Baker D, Mendelsohn A, Westhovens R
The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. J Rheumatol. 2014 Jun; 41(6):1067-76.
The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
Desai SP, Liu CC, Tory H, Norton T, Frits M, Lillegraven S, Weinblatt M, Coblyn J, Yazdany J, Shadick N, Solomon DH
Rheumatoid arthritis quality measures and radiographic progression. Semin Arthritis Rheum. 2014 Aug; 44(1):9-13.
Rheumatoid arthritis quality measures and radiographic progression.
Paudel ML, Shadick N, Weinblatt M, Reed G, Litman HJ, Kremer JM, Pappas DA, Solomon DH
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients. Arthritis Care Res (Hoboken). 2026 Jan; 78(1):54-65.
Development and External Validation of a Multivariable Predictive Model for Progression to Difficult-to-Treat Rheumatoid Arthritis in Biologic-Experienced Patients.
McDermott GC, Jeffway M, Seyok T, Zhang H, Myasoedova E, Davis JM, Giles J, Coblyn J, Helfgott S, Massarotti E, Sands R, Weinblatt ME, Johansson T, Schmajuk G, Michaud K, Perry C, Churchill S, Liao KP
Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and "decentralized" clinical recruitment design. Contemp Clin Trials. 2025 Sep; 156:108000.
Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and "decentralized" clinical recruitment design.
Cheng D, Wang X, McDermott GC, Hanberg JS, Love Z, Zhong K, Jeffway M, Hou J, Panickan V, Sangar R, Qi Y, Melley C, Costa L, Feil D, Matty R, Weisenfeld D, Animashaun A, Schreiner A, Morini S, Rusnak L, Cagan A, Paudel M, Michael Gaziano J, Sauer B, Weinblatt M, Baker J, England B, Ho YL, Cho K, Monach P, Cannon GW, Shadick N, Mikuls TR, Cai T, Liao KP
Inferring rheumatoid arthritis disease activity status from the electronic health records across health systems to enable real-world data studies. medRxiv. 2025 Nov 17.
Inferring rheumatoid arthritis disease activity status from the electronic health records across health systems to enable real-world data studies.
Usiskin IM, Weber BN, Qi Y, Zhong K, Jeffway M, Weinblatt ME, Shadick N, Plutzky J, Liao KP
American journal of preventive cardiology
Comparison of PREVENT with the pooled cohort equation for estimating atherosclerotic cardiovascular disease risk among patients with rheumatoid arthritis. Am J Prev Cardiol. 2025 Dec; 24:101338.
Comparison of PREVENT with the pooled cohort equation for estimating atherosclerotic cardiovascular disease risk among patients with rheumatoid arthritis.
Solomon DH, Santacroce L, Giles JT, Rist P, Everett BM, Liao KP, Paudel M, Shadick NA, Weinblatt M, Bathon JM, Demler O
Biomarkers for Atherosclerotic Cardiovascular Events in Rheumatoid Arthritis: Towards Validation of a Biomarker-Enhanced Risk Model. medRxiv. 2026 Feb 20.
Biomarkers for Atherosclerotic Cardiovascular Events in Rheumatoid Arthritis: Towards Validation of a Biomarker-Enhanced Risk Model.
Immune thrombocytopenic purpura evolving into aplastic anemia in association with Epstein-Barr virus infection. Am J Pediatr Hematol Oncol. 1991; 13(4):465-9.
Immune thrombocytopenic purpura evolving into aplastic anemia in association with Epstein-Barr virus infection.
Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014 Sep; 73(9):1616-25.
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Landewé RB, Smolen JS, Weinblatt ME, Emery P, Dougados M, Fleischmann R, Aletaha D, Kavanaugh A, van der Heijde D
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. Ann Rheum Dis. 2014 Oct; 73(10):1755-60.
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example.
Gillet VG, Solomon DH, Shadick NA, Weinblatt ME, Iannaccone CK, Feldman S, Kim SC
Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis. J Womens Health (Larchmt). 2014 Sep; 23(9):771-6.
Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis.
Weinblatt ME, Westhovens R, Mendelsohn AM, Kim L, Lo KH, Sheng S, Noonan L, Lu J, Xu Z, Leu J, Baker D, Bingham CO
Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis. 2014 Dec; 73(12):2152-9.
Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Genovese MC, van der Heijde DM, Keystone EC, Spindler AJ, Benhamou C, Kavanaugh A, Fudman E, Lampl K, O'Brien C, Duffield EL, Poiley J, Weinblatt ME
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist. J Rheumatol. 2014 Nov; 41(11):2120-8.
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-a antagonist.
Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Keystone EC, Zhukov OS, Abolhosn RW, Popov JM, Britsemmer K, van Kuijk AW, Marotta A
Serum 14-3-3? is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014 Nov; 41(11):2104-13.
Serum 14-3-3? is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.
Weinblatt ME, Scimeca P, James-Herry A, Sahdev I, Kochen J
Transformation of congenital neutropenia into monosomy 7 and acute nonlymphoblastic leukemia in a child treated with granulocyte colony-stimulating factor. J Pediatr. 1995 Feb; 126(2):263-5.
Transformation of congenital neutropenia into monosomy 7 and acute nonlymphoblastic leukemia in a child treated with granulocyte colony-stimulating factor.
an unusual family cancer syndrome manifested in young siblings. Cancer. 1991 Sep 01; 68(5):1068-70.
an unusual family cancer syndrome manifested in young siblings.
Breast nodules as the initial site of relapse in childhood leukemia. Med Pediatr Oncol. 1990; 18(6):510-2.
Breast nodules as the initial site of relapse in childhood leukemia.
Weinblatt ME, Genovese MC, Ho M, Hollis S, Rosiak-Jedrychowicz K, Kavanaugh A, Millson DS, Leon G, Wang M, van der Heijde D
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheumatol. 2014 Dec; 66(12):3255-64.
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Mjaavatten MD, Radner H, Yoshida K, Shadick NA, Frits ML, Iannaccone CK, Kvien TK, Weinblatt ME, Solomon DH
Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis. J Rheumatol. 2014 Dec; 41(12):2370-8.
Inconsistent treatment with disease-modifying antirheumatic drugs: a longitudinal data analysis.
Kitas GD, Abreu G, Jedrychowicz-Rosiak K, Miller JL, Nakov R, Panfilov S, Vencovsky J, Wang M, Weinblatt ME, White WB
Journal of the American Society of Hypertension : JASH
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. J Am Soc Hypertens. 2014 Nov; 8(11):780-90.
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2015 Feb; 44(4):399-404.
Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs.
Doyle TJ, Patel AS, Hatabu H, Nishino M, Wu G, Osorio JC, Golzarri MF, Traslosheros A, Chu SG, Frits ML, Iannaccone CK, Koontz D, Fuhrman C, Weinblatt ME, El-Chemaly SY, Washko GR, Hunninghake GM, Choi AM, Dellaripa PF, Oddis CV, Shadick NA, Ascherman DP, Rosas IO
American journal of respiratory and critical care medicine
Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. Am J Respir Crit Care Med. 2015 Jun 15; 191(12):1403-12.
Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.
Desai RJ, Solomon DH, Weinblatt ME, Shadick N, Kim SC
An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. Arthritis Res Ther. 2015 Apr 13; 17:83.
An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score.
Oswald M, Curran ME, Lamberth SL, Townsend RM, Hamilton JD, Chernoff DN, Carulli J, Townsend MJ, Weinblatt ME, Kern M, Pond CM, Lee A, Gregersen PK
Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders. Arthritis Rheumatol. 2015 Feb; 67(2):344-51.
Modular analysis of peripheral blood gene expression in rheumatoid arthritis captures reproducible gene expression changes in tumor necrosis factor responders.
Liao KP, Playford MP, Frits M, Coblyn JS, Iannaccone C, Weinblatt ME, Shadick NS, Mehta NN
The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015 Jan 30; 4(2).
The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
Brown LE, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Liao KP
Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology (Oxford). 2015 May; 54(5):816-20.
Clinical characteristics of RA patients with secondary SS and association with joint damage.
Smolen JS, Weinblatt ME, van der Heijde D, Rigby WF, van Vollenhoven R, Bingham CO, Veenhuizen M, Gill A, Zhao F, Komocsar WJ, Berclaz PY, Ortmann R, Lee C
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study. Ann Rheum Dis. 2015 Aug; 74(8):1567-70.
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.
Radner H, Yoshida K, Mjaavatten MD, Aletaha D, Frits M, Lu B, Iannaccone C, Shadick N, Weinblatt M, Hmamouchi I, Dougados M, Smolen JS, Solomon DH
Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum. 2015 Oct; 45(2):167-73.
Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort.
Weinblatt ME, Mease P, Mysler E, Takeuchi T, Drescher E, Berman A, Xing J, Zilberstein M, Banerjee S, Emery P
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. Arthritis Rheumatol. 2015 Oct; 67(10):2591-600.
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology. Arthritis Rheumatol. 2015 Oct; 67(10):2555-6.
Editorial: the vital role of randomized controlled trials in Arthritis & Rheumatology.
Radner H, Yoshida K, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Smolen JS, Solomon DH
The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology (Oxford). 2015 Nov; 54(11):2076-84.
The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs.
Emery P, Bingham C, Burmester G, Bykerk V, Furst D, Mariette X, Purcaru O, Coteur G, Vanlunen B, Weinblatt M
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. Value Health. 2015 Nov; 18(7):A707-8.
Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study.
Mariette X, Vencovsky J, Lortholary O, Gomez-Reino J, de Longueville M, Ralston P, Weinblatt M, van Vollenhoven R
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. RMD Open. 2015; 1(1):e000044.
The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.
Emery P, Bingham C, Burmester GR, Bykerk VP, Furst D, Mariette X, Purcaru O, VanLunen B, Weinblatt M
Improvements in Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. Value Health. 2015 Nov; 18(7):A710.
Improvements in Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study.
Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH
Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology (Oxford). 2016 Apr; 55(4):640-8.
Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.
Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B, Stoilov R, Vencovsky J, Weinblatt M
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis. 2015 Dec; 74(12):2123-9.
OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
Pope J, Bingham CO, Fleischmann RM, Dougados M, Massarotti EM, Wollenhaupt J, Duncan B, Coteur G, Weinblatt ME
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. Arthritis Res Ther. 2015 Nov 27; 17:343.
Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
Weinblatt ME, Fleischmann R, van Vollenhoven RF, Emery P, Huizinga TW, Cutolo M, van der Heijde D, Duncan B, Davies O, Luijtens K, Dougados M
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther. 2015 Nov 15; 17:325.
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, Bartalesi F, Lipman M, Mariette X, Lortholary O, Weinblatt ME, Saag M, Smolen J
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis. 2015 Dec; 74(12):2107-16.
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.
Bingham CO, Mendelsohn AM, Kim L, Xu Z, Leu J, Han C, Lo KH, Westhovens R, Weinblatt ME
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Care Res (Hoboken). 2015 Dec; 67(12):1627-36.
Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Sokolove J, Schiff M, Fleischmann R, Weinblatt ME, Connolly SE, Johnsen A, Zhu J, Maldonado MA, Patel S, Robinson WH
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2016 Apr; 75(4):709-14.
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.
Alemao E, Joo S, Kawabata H, Al MJ, Allison PD, Rutten-van Mölken MP, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME
Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. Arthritis Care Res (Hoboken). 2016 Mar; 68(3):308-17.
Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.
Schiff M, Weinblatt ME, Valente R, Citera G, Maldonado M, Massarotti E, Yazici Y, Fleischmann R
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration. RMD Open. 2016; 2(1):e000210.
Reductions in disease activity in the AMPLE trial: clinical response by baseline disease duration.
Fleischmann R, Weinblatt ME, Schiff M, Khanna D, Maldonado MA, Nadkarni A, Furst DE
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2016 07; 68(7):907-13.
Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.
Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Louis Bridges S, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 08 23; 7:12460.
Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.
Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin Exp Rheumatol. 2016 Jul-Aug; 34(4 Suppl 98):69-76.
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016.
Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, Heijde Dv, Vollenhoven Rv, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. Ann Rheum Dis. 2016 10; 75(10):e69.
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.
Sieberts SK, Zhu F, García-García J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Fornés O, Guney E, Li H, Marín MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bellón V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Bridges SL, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM
Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 10 10; 7:13205.
Erratum: Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis.
Iversen MD, Frits M, von Heideken J, Cui J, Weinblatt M, Shadick NA
Physical Activity and Correlates of Physical Activity Participation Over Three Years in Adults With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 10; 69(10):1535-1545.
Physical Activity and Correlates of Physical Activity Participation Over Three Years in Adults With Rheumatoid Arthritis.
Radner H, Yoshida K, Tedeschi S, Studenic P, Frits M, Iannaccone C, Shadick NA, Weinblatt M, Aletaha D, Smolen JS, Solomon DH
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. Arthritis Rheumatol. 2017 04; 69(4):720-727.
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities.
Pulmonary blastoma associated with cystic lung disease. Cancer. 1982 Feb 15; 49(4):669-71.
Pulmonary blastoma associated with cystic lung disease.
Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016 12; 68(12):2857-2866.
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann Rheum Dis. 2017 Jan; 76(1):96-104.
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
Rao DA, Gurish MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, Donlin LT, Henderson LA, Wei K, Mizoguchi F, Teslovich NC, Weinblatt ME, Massarotti EM, Coblyn JS, Helfgott SM, Lee YC, Todd DJ, Bykerk VP, Goodman SM, Pernis AB, Ivashkiv LB, Karlson EW, Nigrovic PA, Filer A, Buckley CD, Lederer JA, Raychaudhuri S, Brenner MB
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017 02 01; 542(7639):110-114.
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis.
Kim H, Cui J, Frits M, Iannaccone C, Coblyn J, Shadick NA, Weinblatt ME, Lee YC
Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken). 2017 12; 69(12):1871-1877.
Fibromyalgia and the Prediction of Two-Year Changes in Functional Status in Rheumatoid Arthritis Patients.
Tedeschi SK, Frits M, Cui J, Zhang ZZ, Mahmoud T, Iannaccone C, Lin TC, Yoshida K, Weinblatt ME, Shadick NA, Solomon DH
Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. Arthritis Care Res (Hoboken). 2017 12; 69(12):1920-1925.
Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry.
Burmester GR, McInnes IB, Kremer J, Miranda P, Korkosz M, Vencovsky J, Rubbert-Roth A, Mysler E, Sleeman MA, Godwood A, Sinibaldi D, Guo X, White WI, Wang B, Wu CY, Ryan PC, Close D, Weinblatt ME
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017 Jun; 76(6):1020-1030.
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Pelcovitz D, Goldenberg B, Kaplan S, Weinblatt M, Mandel F, Meyers B, Vinciguerra V
Posttraumatic stress disorder in mothers of pediatric cancer survivors. Psychosomatics. 1996 Mar-Apr; 37(2):116-26.
Posttraumatic stress disorder in mothers of pediatric cancer survivors.
Scimeca PG, James-Herry AG, Weinblatt ME
Atypical PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis) in a young girl with Fanconi anemia. J Pediatr Hematol Oncol. 1996 May; 18(2):159-61.
Atypical PFAPA syndrome (periodic fever, aphthous stomatitis, pharyngitis, adenitis) in a young girl with Fanconi anemia.
Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. Clin Exp Rheumatol. 1999 Nov-Dec; 17(6 Suppl 18):S66-8.
Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.
Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS
Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum. 1992 Feb; 35(2):129-37.
Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.
Furst DE, Weisman M, Paulus HE, Bulpitt K, Weinblatt M, Polisson R, Zaug M, Kneer J, Van der Auwera P, Stevens RM
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis. J Rheumatol. 2003 Oct; 30(10):2123-6.
Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Rheumatoid arthritis: more aggressive approach improves outlook. Cleve Clin J Med. 2004 May; 71(5):409-13.
Rheumatoid arthritis: more aggressive approach improves outlook.
Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!! Ann Rheum Dis. 2005 Nov; 64(11):1529-31.
Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
Sato M, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Avorn J, Ting G, Shadick NA, Solomon DH
The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28. Arthritis Res Ther. 2006; 8(3):R57.
The validity of a rheumatoid arthritis medical records-based index of severity compared with the DAS28.
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006 Sep; 54(9):2807-16.
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Weinberg RS, Leibowitz D, Weinblatt ME, Kochen J, Alter BP
Juvenile chronic myelogenous leukaemia: the only example of truly fetal (not fetal-like) erythropoiesis. Br J Haematol. 1990 Oct; 76(2):307-10.
Juvenile chronic myelogenous leukaemia: the only example of truly fetal (not fetal-like) erythropoiesis.
Granulomatous lung disease occurring during etanercept treatment. Arthritis Rheum. 2005 Aug 15; 53(4):618-20.
Granulomatous lung disease occurring during etanercept treatment.
Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R
Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol. 1992 Oct; 19(10):1537-41.
Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 02 16; 376(7):652-662.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16; 130(6):478-86.
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med. 1997 Jun; 38(6):888-90.
False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease.
Alarcón GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, St Clair EW, Sundy JS, Alexander RW, Smith GJ, Axiotis CA
Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997 Sep 01; 127(5):356-64.
Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group.
Weinblatt ME, Maier AL, Fraser PA, Coblyn JS
Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998 Feb; 25(2):238-42.
Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, Weinblatt ME
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov; 66 Suppl 3:iii2-22.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, Byrne VM, Kaymakcian MV, Strand V
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum. 1999 Jul; 42(7):1322-8.
Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006 May; 33(5):1021-6.
Rituximab as therapy for refractory polymyositis and dermatomyositis.
Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis. 2006 Jun; 65(6):753-9.
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.
Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006 May; 33(5):854-61.
Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
Kremer JM, Furst DE, Weinblatt ME, Blotner SD
Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol. 1996 Mar; 23(3):459-61.
Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis.
Solomon DH, Shadick NA, Weinblatt ME, Frits M, Iannaccone C, Zak A, Korzenik JR
Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries. BMC Med Res Methodol. 2017 Apr 17; 17(1):59.
Clinical patient registry recruitment and retention: a survey of patients in two chronic disease registries.
Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME
Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992 Apr; 35(4):376-84.
Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate.
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003 Jun; 25(6):1700-21.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Shalon L, Markowitz J, Bialer M, Kahn E, Weinblatt M, Giardiello FM, Luce MC, Daum F
Ovarian neoplasm and endometrioid carcinoma in a patient with Turcot syndrome. J Pediatr Gastroenterol Nutr. 1997 Aug; 25(2):224-7.
Ovarian neoplasm and endometrioid carcinoma in a patient with Turcot syndrome.
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan 28; 340(4):253-9.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology (Oxford). 1999 Nov; 38 Suppl 2:19-23.
The role of current strategies in the future treatment of rheumatoid arthritis.
Mandl LA, Folkerth RD, Pick MA, Weinblatt ME, Gravallese EM
Amyloid myopathy masquerading as polymyositis. J Rheumatol. 2000 Apr; 27(4):949-52.
Amyloid myopathy masquerading as polymyositis.
Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003 Jun; 48(6):1493-9.
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.
Biological agents in rheumatoid arthritis. J Rheumatol Suppl. 1992 Jan; 32:85-8; discussion 88-91.
Biological agents in rheumatoid arthritis.
Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW
Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002 Apr; 103(1):13-21.
Immune function in patients with rheumatoid arthritis treated with etanercept.
Cush JJ, Tugwell P, Weinblatt M, Yocum D
US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol. 1999 May; 26(5):1176-86.
US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis.
Serious liver disease in a patient receiving methotrexate and leflunomide. Arthritis Rheum. 2000 Nov; 43(11):2609-11.
Serious liver disease in a patient receiving methotrexate and leflunomide.
Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, Duclos B, Pasquali JL, El-Gabalawy H, Mathis D, Benoist C
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 2003 Apr; 48(4):944-54.
Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders.
Desai SP, Gravallese EM, Shadick NA, Glass R, Cui J, Frits M, Chibnik LB, Maher N, Weinblatt ME, Solomon DH
Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA. Rheumatology (Oxford). 2010 Mar; 49(3):513-9.
Hand bone mineral density is associated with both total hip and lumbar spine bone mineral density in post-menopausal women with RA.
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum. 2002 Apr; 46(4):851-4.
Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists.
Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, Anderson L, Block S, Small R, Wolfe F
Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol. 1991 Mar; 18(3):334-8.
Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study.
Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH
Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol. 2005 Sep; 32(9):1679-87.
Performance of a rheumatoid arthritis records-based index of severity.
Antimelanoma Differentiation-associated Gene 5 Dermatomyositis. J Rheumatol. 2017 06; 44(6):850-851.
Antimelanoma Differentiation-associated Gene 5 Dermatomyositis.
Quinn T, Bs MF, von Heideken J, Iannaccone C, Shadick NA, Weinblatt M, Iversen MD
Validity of the Nurses' health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis. BMC Musculoskelet Disord. 2017 05 31; 18(1):234.
Validity of the Nurses' health study physical activity questionnaire in estimating physical activity in adults with rheumatoid arthritis.
Targeted therapies: summary clinical trials working group. Ann Rheum Dis. 2006 Nov; 65 Suppl 3:iii89.
Targeted therapies: summary clinical trials working group.
Longterm experience with low dose weekly methotrexate in rheumatoid arthritis. J Rheumatol Suppl. 1990 May; 22:33-8.
Longterm experience with low dose weekly methotrexate in rheumatoid arthritis.
Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, Maher NE, Parker A, Roubenoff R, Izmailova E, Coblyn JS, Weinblatt ME, Shadick NA
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Ann Rheum Dis. 2008 Mar; 67(3):358-63.
Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study.
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Ann Rheum Dis. 2018 01; 77(1):e4.
Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.
Benito-Garcia E, Heller JE, Chibnik LB, Maher NE, Matthews HM, Bilics JA, Weinblatt ME, Shadick NA
Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. J Rheumatol. 2006 Jul; 33(7):1275-81.
Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis.
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Emery P, Keystone EC, Schiff MH, van Riel PL, Weinblatt ME, Weisman MH
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis. 2006 Nov; 65 Suppl 3:iii2-15.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.
Solomon DH, Shadick NA, Weinblatt ME, Zak A, Frits M, Franklin JM
Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement. Arthritis Res Ther. 2017 06 13; 19(1):130.
Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement.
Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosus-associated Hypophysitis. J Rheumatol. 2017 04; 44(4):541-542.
Refractory Syndrome of Inappropriate Secretion of Antidiuretic Hormone in Systemic Lupus Erythematosus-associated Hypophysitis.
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 2008 Oct 15; 59(10):1371-7.
Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1794-803.
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.
Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res (Hoboken). 2013 Mar; 65(3):362-71.
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study.
Weinblatt ME, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, VanLunen B, Ecoffet C, Cioffi C, Emery P
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis Rheumatol. 2017 10; 69(10):1937-1948.
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.
Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, Magilavy DB
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013 Apr; 40(4):369-78.
Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial.
Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, Solomon DH
Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther. 2011 Feb 23; 13(1):R32.
Validation of rheumatoid arthritis diagnoses in health care utilization data.
Fox DA, Faix JD, Coblyn J, Fraser P, Smith B, Weinblatt ME
Thrombotic thrombocytopenic purpura and systemic lupus erythematosus. Ann Rheum Dis. 1986 Apr; 45(4):319-22.
Thrombotic thrombocytopenic purpura and systemic lupus erythematosus.
Endothelial cells degrade extracellular matrix proteins produced in vitro. Thromb Haemost. 1985 Aug 30; 54(2):498-502.
Endothelial cells degrade extracellular matrix proteins produced in vitro.
Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging. 2006; 23(2):167-78.
Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol. 1993 Jun; 20(6):950-2.
Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial.
Kremer JM, Alarcón GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, Palmer WR, Sundy JS, St Clair EW, Alexander RW, Smith GJ, Axiotis CA
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997 Oct; 40(10):1829-37.
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.
Ercan A, Cui J, Hazen MM, Batliwalla F, Royle L, Rudd PM, Coblyn JS, Shadick N, Weinblatt ME, Gregersen P, Lee DM, Nigrovic PA
Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis. Arthritis Res Ther. 2012 Mar 05; 14(2):R43.
Hypogalactosylation of serum N-glycans fails to predict clinical response to methotrexate and TNF inhibition in rheumatoid arthritis.
You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need. Ann Rheum Dis. 2012 Nov; 71(11):1757-60.
You can't always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need.
Seiden MV, O'Donnell WJ, Weinblatt M, Licht J
Vasculitis with recurrent pulmonary hemorrhage in a long-term survivor after autologous bone marrow transplantation. Bone Marrow Transplant. 1990 Nov; 6(5):345-7.
Vasculitis with recurrent pulmonary hemorrhage in a long-term survivor after autologous bone marrow transplantation.
Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M, Barry R, Winslow W, Healy C, Graham RR, Neale BM, Izmailova E, Roubenoff R, Parker AN, Glass R, Karlson EW, Maher N, Hafler DA, Lee DM, Seldin MF, Remmers EF, Lee AT, Padyukov L, Alfredsson L, Coblyn J, Weinblatt ME, Gabriel SB, Purcell S, Klareskog L, Gregersen PK, Shadick NA, Daly MJ, Altshuler D
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007 Dec; 39(12):1477-82.
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.
Oral versus parenteral administration of methotrexate for the treatment of active RA. Nat Clin Pract Rheumatol. 2008 Jul; 4(7):342-3.
Oral versus parenteral administration of methotrexate for the treatment of active RA.
Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, Avorn J, Solomon DH
Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008; 10(4):R95.
Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study.
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis. 2008 Nov; 67(11):1497-8.
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, Winthrop K
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis. 2010 Jan; 69 Suppl 1:i2-29.
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Curtis JR, Jain A, Askling J, Bridges SL, Carmona L, Dixon W, Finckh A, Hyrich K, Greenberg JD, Kremer J, Listing J, Michaud K, Mikuls T, Shadick N, Solomon DH, Weinblatt ME, Wolfe F, Zink A
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010 Aug; 40(1):2-14.e1.
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.
Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010 Sep 30; 363(14):1303-12.
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017 Nov; 76(11):1853-1861.
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Stoll ML, Solomon DH, Batra KL, Simard JF, Karlson EW, Dellaripa PF, Weinblatt ME, Glass R, Shadick NA
TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma. J Clin Rheumatol. 2009 Jun; 15(4):198-200.
TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma.
Boilard E, Lai Y, Larabee K, Balestrieri B, Ghomashchi F, Fujioka D, Gobezie R, Coblyn JS, Weinblatt ME, Massarotti EM, Thornhill TS, Divangahi M, Remold H, Lambeau G, Gelb MH, Arm JP, Lee DM
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis. EMBO Mol Med. 2010 May; 2(5):172-87.
A novel anti-inflammatory role for secretory phospholipase A2 in immune complex-mediated arthritis.
Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF
Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum. 1987 Jan; 30(1):11-7.
Cyclosporin A treatment of refractory rheumatoid arthritis.
Williams ME, Weinblatt M, Rosa RM, Griffin VL, Goldlust MB, Shang SF, Harrison LI, Brown RS
Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis. Clin Pharmacol Ther. 1986 Apr; 39(4):420-4.
Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis.
Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et al. Arthritis Rheum. 2004 Aug; 50(8):2710; author reply 2710-1.
Monitoring guidelines for methotrexate-treated rheumatoid arthritis patients: comment on the article by Yazici et al.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006 Aug; 38(8):904-9.
Principal components analysis corrects for stratification in genome-wide association studies.
van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone EC
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res (Hoboken). 2011 Jan; 63(1):128-34.
American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, Baumgartner SW, Park GS, Mancini EL, Genovese MC
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):373-82.
Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, White WI, Ryan PC, Godwood A, Albulescu M, Close D, Burmester GR
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis Rheumatol. 2018 01; 70(1):49-59.
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
Weinblatt ME, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Jaworski J, Racewicz A, Pileckyte M, Jedrychowicz-Rosiak K, Cheong SY, Ghil J
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Arthritis Rheumatol. 2018 01; 70(1):40-48.
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Ruderman EM, Crawford JM, Maier A, Liu JJ, Gravallese EM, Weinblatt ME
Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis. Br J Rheumatol. 1997 Feb; 36(2):210-3.
Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis.
Sperling RI, Weinblatt M, Robin JL, Ravalese J, Hoover RL, House F, Coblyn JS, Fraser PA, Spur BW, Robinson DR
Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum. 1987 Sep; 30(9):988-97.
Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis.
Acute interstitial pneumonitis and hypoxemia associated with rheumatoid arthritis. Med Times. 1981 Jun; 109(6):58-62, 66-8.
Acute interstitial pneumonitis and hypoxemia associated with rheumatoid arthritis.
Weinblatt ME, Germain BF, Kremer JM, Wall BA, Weisman MH, Maier AL, Coblyn JS
Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin A. Results of a randomized, placebo-controlled trial. Arthritis Rheum. 1994 Sep; 37(9):1321-5.
Lack of a renal-protective effect of misoprostol in rheumatoid arthritis patients receiving cyclosporin A. Results of a randomized, placebo-controlled trial.
Sahdev I, Weinblatt ME, Lester H, Finger PT, Kochen J
Primary ocular recurrence of leukemia following bone marrow transplant. Pediatr Hematol Oncol. 1993 Jul-Sep; 10(3):279-82.
Primary ocular recurrence of leukemia following bone marrow transplant.
Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, Weissman BN
The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum. 1993 May; 36(5):613-9.
The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin.
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M
Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis. 1999 Nov; 58 Suppl 1:I129-30.
Access to disease modifying treatments for rheumatoid arthritis patients.
Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis. 2003 Nov; 62 Suppl 2:ii94-6.
Rheumatoid arthritis in 2003: where are we now with treatment?
Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME
Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002 May; 46(5):1171-6.
Etanercept in the treatment of adult patients with Still's disease.
Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, Li Y, Kurreeman FA, Zhernakova A, Hinks A, Guiducci C, Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJ, Costenbader KH, Criswell LA, Crusius JB, Cui J, de Bakker PI, De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, Huizinga TW, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan AW, Padyukov L, Posthumus MD, Radstake TR, Reid DM, Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, van der Helm-van Mil AH, van der Horst-Bruinsma IE, van der Schoot CE, van Riel PL, Weinblatt ME, Wilson AG, Wolbink GJ, Wordsworth BP, Wijmenga C, Karlson EW, Toes RE, de Vries N, Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, Klareskog L, Plenge RM
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet. 2010 Jun; 42(6):508-14.
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.
Furst DE, Halbert RJ, Bingham CO, Fukudome S, Anderson L, Bonafede P, Bray V, Cohen SB, Sherrer YR, St Clair EW, Tesser JR, Weinblatt M, Dubois RW
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. Rheumatology (Oxford). 2008 Feb; 47(2):194-9.
Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel.
Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL
Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. J Rheumatol. 2008 Aug; 35(8):1683-5.
Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis.
Chronic myopathy with a partial deficiency of the carnitine palmityltransferase enzyme. Arch Neurol. 1989 May; 46(5):575-6.
Chronic myopathy with a partial deficiency of the carnitine palmityltransferase enzyme.
Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA
Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford). 2011 Jan; 50(1):40-6.
Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study.
Lee JS, Wang J, Martin M, Germer S, Kenwright A, Benayed R, Spleiss O, Platt A, Pilson R, Hemmings A, Weinblatt ME, Kaplowitz N, Krasnow J
Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics. 2011 Jul; 21(7):365-74.
Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab.
Chang HH, Tai TS, Lu B, Iannaccone C, Cernadas M, Weinblatt M, Shadick N, Miaw SC, Ho IC
PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis. PLoS One. 2012; 7(3):e33067.
PTPN22.6, a dominant negative isoform of PTPN22 and potential biomarker of rheumatoid arthritis.
Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013 Mar; 72(3):381-9.
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
Fraser PA, Stern SH, Coblyn JS, Weinblatt ME, Holdsworth DE, Green P, Shriner S, Mindnich D, Larson M
Journal of the National Medical Association
Immunogenetic and racial determinants of gold toxicity in rheumatoid arthritis. J Natl Med Assoc. 1988 Feb; 80(2):162-5.
Immunogenetic and racial determinants of gold toxicity in rheumatoid arthritis.
Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME
Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. J Rheumatol. 2007 Sep; 34(9):1817-22.
Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, Paller AS, Pariser DM, Weinblatt M, Zimmerman G
AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003 Nov; 49(5):897-9.
AAD consensus statement on psoriasis therapies.
Clinical orthopaedics and related research
Disease-modifying agents and experimental treatments of rheumatoid arthritis. Clin Orthop Relat Res. 1991 Apr; (265):103-15.
Disease-modifying agents and experimental treatments of rheumatoid arthritis.
Roubenoff R, Beckman E, Weinblatt M, Shadick N, Gregersen PK
Biological significance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis. Ann Intern Med. 2008 Mar 04; 148(5):403; author reply 403-4.
Biological significance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis.
Newer immunosuppressive therapies for rheumatoid arthritis. Crit Care Med. 1990 Feb; 18(2 Suppl):S126-31.
Newer immunosuppressive therapies for rheumatoid arthritis.
Desai SP, Lu B, Szent-Gyorgyi LE, Bogdanova AA, Turchin A, Weinblatt M, Coblyn J, Greenberg JO, Kachalia A, Solomon DH
Increasing pneumococcal vaccination for immunosuppressed patients: a cluster quality improvement trial. Arthritis Rheum. 2013 Jan; 65(1):39-47.
Increasing pneumococcal vaccination for immunosuppressed patients: a cluster quality improvement trial.
Mandel SJ, Brent GA, Weinblatt M, Larsen PR
Thyroid : official journal of the American Thyroid Association
Prospective studies of thyroid function in patients receiving gold therapy. Thyroid. 1995 Apr; 5(2):113-6.
Prospective studies of thyroid function in patients receiving gold therapy.
Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, Gall E
Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum. 1994 Oct; 37(10):1492-8.
Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study.
Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar; 9(3):e1003394.
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis.
Alemao E, Guo Z, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME
Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study. Semin Arthritis Rheum. 2018 04; 47(5):630-638.
Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
Cui J, Taylor KE, Destefano AL, Criswell LA, Izmailova ES, Parker A, Roubenoff R, Plenge RM, Weinblatt ME, Shadick NA, Karlson EW
Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis. Mol Med. 2009 May-Jun; 15(5-6):136-43.
Genome-wide association study of determinants of anti-cyclic citrullinated peptide antibody titer in adults with rheumatoid arthritis.
Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, Ergul E, Conta JH, Korn JM, McCarroll SA, Gorham JM, Gabriel S, Altshuler DM, Quintanilla-Dieck Mde L, Artunduaga MA, Eavey RD, Plenge RM, Shadick NA, Weinblatt ME, De Jager PL, Hafler DA, Breitbart RE, Seidman JG, Seidman CE
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet. 2009 Aug; 41(8):931-5.
De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot.
Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs). Scand J Rheumatol Suppl. 1989; 83:7-10.
Drug interactions with non steroidal anti-inflammatory drugs (NSAIDs).
Sullivan MB, Iannaccone C, Cui J, Lu B, Batra K, Weinblatt M, Shadick NA
Evaluation of selected rheumatoid arthritis activity scores for office-based assessment. J Rheumatol. 2010 Dec; 37(12):2466-8.
Evaluation of selected rheumatoid arthritis activity scores for office-based assessment.
Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011 Feb; 63(2):337-45.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL
Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011 May; 38(5):855-62.
Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.
Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW
Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology (Oxford). 2009 Jun; 48(6):613-7.
Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.
The end of rheumatoid factor as we know it? Arthritis Rheum. 2011 May; 63(5):1170-2.
The end of rheumatoid factor as we know it?
Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, Iannaccone CK, Weinblatt ME, Solomon DH
Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther. 2012 Mar 19; 14(2):R68.
Sustained rheumatoid arthritis remission is uncommon in clinical practice.
Solomon DH, Stedman M, Licari A, Weinblatt ME, Maher N, Shadick N
Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. Arthritis Rheum. 2007 Mar 15; 57(2):234-9.
Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries.
Pfinsgraff J, Buckingham RB, Killian PJ, Keister SR, Brereton WF, Weinblatt ME, George DL, Arnett FC
Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome. Semin Arthritis Rheum. 1986 Nov; 16(2):118-25.
Palmar fasciitis and arthritis with malignant neoplasms: a paraneoplastic syndrome.
Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, Albulescu M, Michaels MA, Guo X, Close D, Weinblatt M
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor a Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2018 05; 70(5):679-689.
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor a Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
A PC database to facilitate treatment of pediatric hematology/oncology patients. Pediatr Hematol Oncol. 1995 May-Jun; 12(3):259-69.
A PC database to facilitate treatment of pediatric hematology/oncology patients.
Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Holers VM, Glass DN, Chen PP, Bridges SL, Weinblatt ME, Paulus HE, Tsao BP
A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis. Arthritis Rheum. 2010 Oct; 62(10):2864-75.
A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.
Winthrop KL, Strand V, van der Heijde D, Mease P, Crow M, Weinblatt M, Bathon J, Burmester GR, Dougados M, Kay J, Mariette X, Van Vollenhoven R, Sieper J, Melchers F, Breedfeld FC, Kalden J, Smolen JS, Furst DE
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. Clin Immunol. 2018 01; 186:87-93.
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017.
Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan; 65(1):28-38.
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
Pelcovitz D, Libov BG, Mandel F, Kaplan S, Weinblatt M, Septimus A
Posttraumatic stress disorder and family functioning in adolescent cancer. J Trauma Stress. 1998 Apr; 11(2):205-21.
Posttraumatic stress disorder and family functioning in adolescent cancer.
Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Mar; 46(3):614-24.
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH
Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum. 2005 Feb 15; 53(1):61-6.
Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel.
Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998 Feb 15; 101(4):746-54.
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.
Weinblatt M, Helfgott S, Coblyn J, Spragg J, Uedelhoven WM, Tumeh S, Sperling R, Lorenz R, Maier A, Weber P
The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis. Arthritis Rheum. 1991 Apr; 34(4):481-5.
The effects of cyclosporin A on eicosanoid excretion in patients with rheumatoid arthritis.
The best of times, the worst of times: rheumatology 2001. Arthritis Rheum. 2002 Mar; 46(3):567-73.
The best of times, the worst of times: rheumatology 2001.
Tesser JR, Pisko EJ, Hartz JW, Weinblatt ME
Chronic liver disease and Still's disease. Arthritis Rheum. 1982 May; 25(5):579-82.
Chronic liver disease and Still's disease.